Advanced melanoma

New six-and-a-half-year data from CheckMate -067, a randomized, double-blind, phase 3 clinical trial, demonstrating durable improvement in survival with first-line...


The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...


The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within...


Treatment of patients with BRAF V600–mutant melanoma includes BRAF/MEK-inhibitor combinations based on demonstrated benefits on progression-free survival ( PFS )...


This is the first randomized trial testing the addition of an oncolytic virus to an immune checkpoint inhibitor for advanced...


Treatment with checkpoint inhibitors or targeted therapy improves outcomes in patients with BRAF V600–mutant advanced melanoma; however, many patients subsequently...


The European Commission has granted marketing authorization in the European Union ( EU ) for the precision oncology treatment Vitrakvi...


The European Commission ( EC ) has approved Keytruda , an anti-PD-1 therapy, as monotherapy or in combination with Platinum...


Early data from two clinical trials have shown reduced survival with Keytruda ( Pembrolizumab ) and Tecentriq ( Atezolizumab )...


The FDA ( U.S. Food and Drug Administration ) has approved Larotrectinib ( Vitrakvi ), the first oral TRK inhibitor. The...


New immunotherapy treatments offer a remarkable chance for survival for patients with advanced melanoma and hard-to-treat cancers of the bladder,...


In a letter published in the cancer journal Annals of Oncology, researchers led by Jean-Philippe Spano, at Pitie-Salpetriere Hospital AP-HP...


Researchers at the University of Texas MD Anderson Cancer Center in Houston, have found a link between microbes in the...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for the...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death...


The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In...


Agents that induce an immune response against tumors by altering T-cell regulation have increased survival times of patients with advanced-stage...


The U.S. Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, for the...


Updated data from the advanced non-small cell lung cancer ( NSCLC ) patient cohort of the ongoing phase 1/2 ECHO-202...


Updated data from the ongoing phase 1/2 ECHO-204 trial evaluating the safety and efficacy of Epacadostat, an oral selective IDO1...